Capital Increase in Genmab as a Result of Employee Warrant Exercise


Summary: Genmab A/S increases its share capital by 131,541 shares as a 
result of employee warrant exercise.                                            

Copenhagen, Denmark; June 1, 2007 - Genmab A/S (CSE: GEN) has decided to        
increase its share capital by 131,541 shares as a consequence of the exercise of
employee warrants.                                                              

The increase is effected without any preemption rights for the existing         
shareholders of the company or others. The shares are subscribed in cash at the 
following prices per share of nominally DKK 1: 47,995 shares at DKK 33.70,      
23,450 shares at DKK 37.00, 12,975 shares at DKK 62.50, 6,125 shares at DKK     
86.00, 6,000 shares at DKK 89.50, 1,125 shares at DKK 97.00, 2,875 shares at DKK
101.00, 7,311 shares at DKK 116.00, 625 shares at DKK 130.00, 13,625 shares at  
DKK 139.50, 3,849 shares at DKK 184.00 and 5,586 shares at DKK 210.50. Proceeds 
to the company are approximately DKK 9.5 million (approx. USD 1.7 million). The 
increase corresponds to approx. 0.30 % of the company's share capital.          
                                                                                
The new shares are ordinary shares without any special rights and are freely    
transferable negotiable instruments. The new shares shall give rights to        
dividends and other rights in relation to the company as of subscription, i.e.  
inter alia full rights to dividends for the financial year 2007. The new shares 
will be listed on the Copenhagen Stock Exchange after registration with the     
Danish Commerce and Companies Agency. Genmab A/S' current share capital amounts 
to DKK 44,333,015 and will after the capital increase be DKK 44,464,556. The    
capital increase is expected to be finalized shortly.                           

About Genmab A/S                                                                
Genmab A/S is a biotechnology company that creates and develops human antibodies
for the treatment of life-threatening and debilitating diseases. Genmab has     
numerous products in development to treat cancer, infectious disease, rheumatoid
arthritis and other inflammatory conditions, and intends to continue assembling 
a broad portfolio of new therapeutic products. In addition, Genmab has developed
UniBody(TM), a new proprietary technology that creates a stable, smaller        
antibody format.  Genmab has operations in Europe and the US. For more          
information about Genmab, visit www.genmab.com.                                 

This press release contains forward looking statements. The words “believe”,    
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify    
forward looking statements. Actual results or performance may differ materially 
from any future results or performance expressed or implied by such statements. 
The important factors that could cause our actual results or performance to     
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical   
trials including unforeseen safety issues, uncertainties related to product     
manufacturing, the lack of market acceptance of our products, our inability to  
manage growth, the competitive environment in relation to our business area and 
markets, our inability to attract and retain suitably qualified personnel, the  
unenforceability or lack of protection of our patents and proprietary rights,   
our relationships with affiliated entities, changes and developments in         
technology which may render our products obsolete, and other factors. Genmab is 
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to      
actual results, unless this is required by law.                                 

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);  
HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-TAC(TM); HuMax-HepC(TM), HuMax-CD38(TM);
HuMax-ZP3(TM); and UniBody(TM) are all trademarks of Genmab A/S.                

Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M: 
+45 25 27 47 13, E: hth@genmab.com                                              
                                                                                
Stock Exchange Release no. 23/2007

Attachments

23 capital increase_010607_uk.pdf